Posted by Michael Wonder on 18 Jan 2023
Ultomiris approved in Canada for adults with generalied myasthenia gravis
17 January 2023 - First and only long acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalised myasthenia gravis.
Ultomiris (ravulizumab) has been approved in Canada for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive.
